WuXi XDC Cayman, Inc. · HKEX:2268
WuXi XDC Cayman — WuXi XDC — H1 2024 Earnings Presentation
29 slides from WuXi XDC Cayman's earnings presentation, Aug 21, 2024
Slide 1: WuXi XDC 2024 Interim Results
Stock Code: 2268.HK WuXi XDC 2024 Interim Results 21 August, 2024 | Hong Kong
Slide 2: Disclaimer
Disclaimer Forward-Looking Statements This presentation may contain certain “forward-looking statements” which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our management. Although
Slide 3: WuXi XDC: Global Leading All-in-One CRDMO Dedicated to ADC and Broader Bioconjugates Market
WuXi XDC: Global Leading All-in-One CRDMO Dedicated to ADC and Broader Bioconjugates Market Table of Contents Germany U.S. Wuxi West Coast East Coast China Shanghai 1. 2024 Interim Key Highlights Changzhou Singapore US/EN/Asia 2. Latest XDC Industry Trend Operations 3. Operation and Business Updates
Slide 4: Key Highlights
b 01 Key Highlights
Slide 5: Superior Financial Results and Strong Project Momentum in 1H 2024
Superior Financial Results and Strong Project Momentum in 1H 2024 Adj. EBITDA 01 Projects and Customers 02 Key Financial Results Global customers Revenue Gross Profit 419 (cumulatively*) 1,665 Mn RMB 535 Mn RMB Ongoing iCMC projects, 167 with 26 newly signed 68% YoY 133% YoY Net Profit Adj. Net Prof
Slide 6: Latest XDC Industry Trend
b 02 Latest XDC Industry Trend ESE
Slide 7: ADC/XDC Continue to be the Focus of the Healthcare Industry Globally
ADC/XDC Continue to be the Focus of the Healthcare Industry Globally ADC/XDC M&A deals Representative ADC/XDC collaboration/ Global ADC/XDC Primary Market since Jun 2023 licensing deals(≥$1 bn) since Dec 2023 Financing Deals (2020-1H 2024) Number of Deals Total Amount Target Buyer Deal size Date Lic
Slide 8: ADC/XDC Global Late Stage Trials with Diversified Targets Continue to Enrich the Pipeline
ADC/XDC Global Late Stage Trials with Diversified Targets Continue to Enrich the Pipeline of Next Generation Bioconjugate Drugs Global Late Stage Trials in ADC/XDC ✓ Among 4 BLA Submissions as of 1H 2024 • HER2 • TROP2 • HER3 Phase II 540+ ✓ Top Targets among 130+ Phase III Trials • CLDN18.2 • B7H3
Slide 9: Latest R&D Trends of Bioconjugates: Explore Different Therapeutic Areas
Latest R&D Trends of Bioconjugates: Explore its Application in Different Therapeutic Areas and Expand its Commercial Potential 1 ADC drugs continue to develop commercial 3 ADC combo with other drugs especially I/O value by expanding into different indications, are becoming clinical focus or advancin
Slide 10: Operation and Business Updates
03 Operation and Business Updates
Slide 11: Our “Enable – Follow – Win” Business Model Continues to Win Customers and Projects Globally
Our “Enable – Follow – Win” Business Model Continues to Win Customers and Projects Globally Number of Projects Through “Enable – Follow – Win” Strategy “R” "Research”: Enable discovery to PCC 538 Discovery(1) / 427 (3) 41 projects advanced from discovery to iCMC stage (1) 91 Preclinical / 84 (3) "De
Slide 12: 9 PPQ Projects with Diverse Targets From Global Customers
9 PPQ Projects with Diverse Targets From Global Customers, with Potential Multiple BLA Submissions in 2024 and Beyond Global Projects Diversified Targets • Currently signed 9 PPQ high-quality projects from 9 PPQ • 9 PPQ projects cover both MNC and biotech Projects multiple innovative customers targe
Slide 13: High Quality and Rich Global Customer Portfolio
High Quality and Rich Global Customer Portfolio A Fast-Growing Customer Base… Geographic Breakdown of New Customers in 1H 2024 Cumulative +74 419 47% 345 +80 265 30% 12% 11% North America China Europe APAC(ex. CN) 2022 2023 1H 2024 We Continued to Win and Retain High-Quality Customers …High Profile
Slide 14: Our Vastly Experienced and Leading Technology Platform
Our Vastly Experienced and Leading Technology Platform: Unmatched Diverse Solutions From 11,000+ Molecules .. With Various Targets and Experience Total 705 Diversified Projects .. Payload-linker Technologies Diversified Targets ADC Ongoing Projects HER3 CLDN18.2 11,000+ CLDN6 EGFR /HER3 Bioconjugate
Slide 15: Enable Customers With Cutting-edge Conjugation and Payload-Linker Technologies
Enable Customers With Cutting-edge Conjugation and Payload-Linker Technologies: Innovation by In-house and External Partnerships ✓ Enable Customer’s ✓ In-house Proprietary ✓ External Partnerships Technologies in CMC Conjugation Technology Development and MFG 10+ • iGDC (intelligent Glycotransferase
Slide 16: Our Global GMP-Compliant Manufacturing Facilities
Our Global GMP-Compliant Manufacturing Facilities Wuxi site Changzhou site Shanghai site Discovery & Research Current operational capacity: Discovery, Development - Antibody intermediate & Manufacturing Manufacturing - Bioconjugate - Payload-linkers - Antibody intermediate Development - Payload-link
Slide 17: Wuxi Site: All-in-One Manufacturing Facility Operational and Ramping Up Rapidly
Wuxi Site: All-in-One Manufacturing Facility Operational and Ramping Up Rapidly BCM2 L2 DP3 New Lab/Office XDC Wuxi Site Expansion All-in-One manufacturing facility with expanded capacity and a robust supply chain! The 1st mAb/DS dual function line Quickly initiated the build-up of additional Other
Slide 18: Singapore Site: Construction Ongoing as Planned
Singapore Site: Construction Ongoing as Planned Construction Status - June 2024 Facilities Singapore’s Tuas 22,000 sq meters Biomedical Park Capacities and Capabilities Commercial scale GMP manufacture Operational by late 2025/early 2026 ✓ mAb intermediate: 50 L to 2,000 L ✓ ADCs / conjugates DS: up
Slide 19: Financial Performance
b 04 Financial Performance
Slide 20: Superior Financial Results and Strong Growth Momentum
Superior Financial Results and Strong Growth Momentum Revenue Gross Profit RMB mm RMB mm 26.4% 26.3% 23.1% 32.1% 2,123.8 1,665.2 559.6 535.3 990.4 993.5 261.1 229.4 2022 2023 1H 2023 1H 2024 2022 2023 1H 2023 1H 2024 EBITDA(1) and Adjusted EBITDA(2)(3) Net Profit and Adjusted Net Profit(2)(3) RMB mm
Slide 21: Continuous Fast Growth of Backlog and Newly Signed Contract Values
Continuous Fast Growth of Backlog and Newly Signed Contract Values Number of Projects Through “Enable – Follow – Win” Strategy Backlog Amount Grew Significantly in 1H 2024 USD mm “R” 538 Discovery(1) / 427 (3) 842 91 Preclinical / 84 (3) 579 411 318 47 Phase I / 38 (3) 76 ongoing 2022 2023 1H 2023 1
Slide 22: High Quality Development of Revenue Across All Geographic Regions
High Quality Development of Revenue Across All Geographic Regions Revenue Percentage by Project Status 1H 2023 2023 FY 1H 2024 • With more projects progressing towards Total Revenue 993.5 2,123.8 1,665.2 the advanced stage, the revenue from (RMB mm) post-IND projects accounts for ~61% of the total r
Slide 23: Continuous Margin Improvement
Continuous Margin Improvement Gross Profit Margin Rosed by 9.0 pps Improved margins mainly attributed by … + 5.8 pps ➢ Wuxi site facilities ramped up quickly and reached + 9.0 pps higher utilization ratio both in DS and DP production 32.1% 26.4% 26.3% 23.1% ➢ Enhanced overall operation efficiency ➢
Slide 24: Capex and Global Facilities’ Expansion
Capex and Global Facilities’ Expansion Capex in 1H 2024 vs. 1H 2023 Singapore Site Construction Progress RMB mm • Our modular facility pre-fabrication is well on track and 521.8 will be delivered to the site in September 2024. 247.8 • Overall site construction is progressing smoothly, and we expect
Slide 25: Summary and Q&A
Summary and Q&A Projects and Customers Financial Highlights Revenue Margins 419 1,665 Mn RMB, 68% YoY Global customers cumulatively Gross Profit GPM 32.1%, 167 We continue to deliver 535 Mn RMB, 133% YoY 9.0pps Ongoing iCMC projects, with superior performance 26 newly signed Net Profit NPM despite t
Slide 26: Appendix
Appendix
Slide 27: Consolidated Income Statements
Consolidated Income Statements (unaudited) 27
Slide 28: Consolidated Balance Sheets
Consolidated Balance Sheets (unaudited) 28
Slide 29: Consolidated Balance Sheets (Cont’d)
Consolidated Balance Sheets (Cont’d) (unaudited) 29